MARINE MICROBE-DERIVED LEADS FOR ALZHEIMERS DISEASE

描述：（逐字引用申请人的摘要）本发明的目的是 应用是从海洋微生物中引入新的药效团， 阿尔茨海默病（AD）的潜在治疗剂。的一个主要 AD的组织病理学标志是存在于 特定的神经元病灶。这些斑块，大多由不溶性 在神经元和支持（神经胶质）细胞中产生的类淀粉β肽（Abeta）， 与AD中的神经元细胞死亡有关。AD研究的一个主要焦点 涉及寻找可以减少 不溶性Abeta Oceanix Biosciences Corp正在努力发现新的 和海洋微生物的专有药效团。研究计划包括 为了测试来自这些微生物的不同提取物， 人神经胶质瘤（H4）细胞。在H4中发现的Abeta生产抑制剂 将在使用原代神经元培养物的二次筛选中测试筛选 （大鼠）。从这些细胞生产Abeta将用已知的方法进行验证。 在筛选海洋微生物提取物之前，提取物 还将测试细胞毒性和细胞凋亡。 拟定商业应用： 我们提出的商业应用是这项研究计划的结果， 与开发治疗老年痴呆症的新药有关 疾病有希望的新化学实体将进一步跟踪，看看它们是否 是适合人类使用的候选药物。

DESCRIPTION: (Verbatim from the Applicant's Abstract) The goal of this application is to introduce novel pharmacophores from marine microorganisms as potential therapeutic agents for Alzheimer's Disease (AD). One of the major histopathological hallmarks of AD is the formation of senile plaques present in specific neuronal foci. These plaques, mostly composed of insoluble anyloid-beta peptides (Abeta) produced in neurons and supporting (glial) cells, are associated with neuronal cell death in AD. A major focus of AD research involves a search for therapeutic agents that can reduce the formation of insoluble Abeta. Oceanix Biosciences Corp is making efforts to discover novel and proprietary pharmacophores from marine microbes. The research plan included to test different extracts from these microorganisms in a bioassay for Abeta in human neuroglioma (H4) cells. Inhibitors of Abeta production found in the H4 screen will be tested in a secondary screen using primary neuronal cultures (rat). Production of Abeta from these cells will be validated with known affectors of Abeta prior to screening marine microorganism extracts. Extracts will also be tested for cytotoxicity and apoptosis. PROPOSED COMMERCIAL APPLICATION: The commercial application we propose are a result of this research plan, are related to the development of new pharmaceuticals for treating Alzheimer's Disease. Promising new chemical entities will be followed further to see if they are appropriate drug candidates for human use.